Xu Huizhe, Wu Zhisheng, Tang Jiamei, Gan Yu, Li Jicheng, Yu Yingying, Chen Yi, Sui Rui, Liu Jia, Zhang Ye, Piao Haozhe
Central Laboratory, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, P R PR China; Institute of Cancer Medicine, Dalian University of Technology, No.2 Linggong Road, Ganjingzi District, Dalian 116024, Liaoning Province, P R PR China.
Central Laboratory, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, P R PR China; Department of Neurosurgery, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, P R PR China.
Phytomedicine. 2025 Aug;144:156917. doi: 10.1016/j.phymed.2025.156917. Epub 2025 May 30.
BACKGROUND: Glioblastoma (GBM) is the most malignant primary intracranial tumor. Owing to its unfavorable prognosis and frequent recurrence, patient outcomes are poor even with standard treatment. Recent studies have reported that FTY720, a structurally modified sphingosine extracted from Cordyceps sinensis, has preclinical antitumor efficacy and can regulate the microenvironment of GBM. However, the mechanism and effective utilization of FTY720, i.e., avoiding adverse reactions during systemic application in GBM remain unclear. PURPOSE: This study aimed to investigate the mechanisms by which FTY720 suppresses GBM growth and to explore the ability of a novel liposomal nanoparticle carrying FTY720 to directly target GBM. METHODS: Molecular, cytological, and histological techniques were employed to assess the effects of FTY720 on GBM cells, both in vitro and in vivo. Ferroptosis induction and its regulatory mechanisms were explored using a combination of reactive oxygen species (ROS), malondialdehyde (MDA) and glutathione (GSH) assays; transmission electron microscopy (TEM); and orthotopic GBM mouse model experiments. A nanoparticle drug delivery system based on liposomes (GF2-FTY720-LPs) was synthesized by thin film dispersion. RESULTS: Our study revealed that FTY720 induces ferroptosis in GBM cells through the AMPK-mTOR-GPX4 pathway, and that ginsenoside F2 (GF2) plays a synergistic role by reducing GSH levels. GF2-FTY720-LPs show superior targeting ability and potent inhibition of GBM in vivo, penetrating the blood-brain barrier and overcoming the shortcomings of systemic FTY720 application. CONCLUSION: Our findings revealed the inhibitory effect of FTY720 on GBM, and the great ability of GF2-FTY720-LPs to target GBM. GF2-FTY720-LPs penetrate the blood-brain barrier without relying on specific conditions such as a magnetic field, light, or heat. GF2-FTY720-LPs achieved precise localization by targeting the highly expressed GLUT1 in GBM cells, and efficiently released drugs in the acidic tumor microenvironment, which significantly reduced the off-target toxicity and enhanced the antitumor efficacy compared with traditional chemotherapy drugs. In summary, our study provides new insights and a theoretical basis for selecting and researching GBM treatment.
背景:胶质母细胞瘤(GBM)是最恶性的原发性颅内肿瘤。由于其预后不佳且频繁复发,即使采用标准治疗,患者的预后也很差。最近的研究报告称,从冬虫夏草中提取的结构修饰的鞘氨醇FTY720具有临床前抗肿瘤功效,并且可以调节GBM的微环境。然而,FTY720的作用机制和有效利用,即在GBM全身应用过程中避免不良反应,仍不清楚。 目的:本研究旨在探讨FTY720抑制GBM生长的机制,并探索携带FTY720的新型脂质体纳米颗粒直接靶向GBM的能力。 方法:采用分子、细胞学和组织学技术评估FTY720对GBM细胞的体内外作用。通过活性氧(ROS)、丙二醛(MDA)和谷胱甘肽(GSH)检测、透射电子显微镜(TEM)以及原位GBM小鼠模型实验相结合的方法,探索铁死亡诱导及其调控机制。采用薄膜分散法合成了基于脂质体的纳米颗粒药物递送系统(GF2-FTY720-LPs)。 结果:我们的研究表明,FTY720通过AMPK-mTOR-GPX4途径诱导GBM细胞发生铁死亡,人参皂苷F2(GF2)通过降低GSH水平发挥协同作用。GF2-FTY720-LPs在体内表现出卓越的靶向能力和对GBM的强效抑制作用,能够穿透血脑屏障,克服FTY720全身应用的缺点。 结论:我们的研究结果揭示了FTY720对GBM的抑制作用,以及GF2-FTY720-LPs对GBM的强大靶向能力。GF2-FTY720-LPs无需依赖磁场、光或热等特定条件即可穿透血脑屏障。GF2-FTY720-LPs通过靶向GBM细胞中高表达的GLUT1实现精确定位,并在酸性肿瘤微环境中有效释放药物,与传统化疗药物相比,显著降低了脱靶毒性并增强了抗肿瘤疗效。总之,我们的研究为GBM治疗的选择和研究提供了新的见解和理论依据。
Cochrane Database Syst Rev. 2018-2-6
Cancer Commun (Lond). 2025-3-14
Cochrane Database Syst Rev. 2022-5-20
ACS Appl Mater Interfaces. 2025-6-18